Cenvacibart not checked

Regeneron · REGN7508

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
12 active
16 in total · 10 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-bart: artificial immunoglobulins WHO name stem
Tested for
Venous Thromboembolism (VTE) (3 trials), Atrial Fibrillation (AF) (3 trials), Symptomatic Venous Thromboembolism (VTE), Peripheral Artery Disease (PAD), Secondary Stroke, Cancer-Associated Thrombosis (CAT), End-Stage Kidney Disease (ESKD)
Main trialPhase 3
“This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the…”In the company’s words, NCT07015905 on ClinicalTrials.gov
Other names
REGN7508

Other drugs for Venous Thromboembolism (VTE)

All 7 drugs for Venous Thromboembolism (VTE)

Coming up12

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 20 Feb 2027 REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Phase 3Recruiting 17 May 2027 REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Phase 3Recruiting 28 Mar 2029 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
Phase 3Recruiting 25 Jun 2029 Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
Phase 3Recruiting 18 Aug 2029 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Phase 3Recruiting 11 Sep 2029 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Phase 3Not yet recruiting 15 Dec 2029 A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
Phase 3Recruiting 23 Jan 2030 REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Phase 3Recruiting 18 Jul 2031 Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Phase 2Recruiting 9 Feb 2027 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
Phase 1Not yet recruiting 23 Mar 2027 Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations
Phase 1Recruiting 2 Apr 2027 Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis
Phase 2Completed 19 Nov 2024 A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants
Phase 2Completed 27 Mar 2026 A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
Phase 1Completed 17 Sep 2024 A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
Phase 1Completed 7 Apr 2025 Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cenvacibart

Following is part of Solo: you see every change to Cenvacibart the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in